JP2008521934A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521934A5 JP2008521934A5 JP2007544571A JP2007544571A JP2008521934A5 JP 2008521934 A5 JP2008521934 A5 JP 2008521934A5 JP 2007544571 A JP2007544571 A JP 2007544571A JP 2007544571 A JP2007544571 A JP 2007544571A JP 2008521934 A5 JP2008521934 A5 JP 2008521934A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- administered
- compound
- combination
- atazanavir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 15
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 13
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 13
- 229960003277 atazanavir Drugs 0.000 claims 13
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 13
- 229940126062 Compound A Drugs 0.000 claims 12
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 230000037396 body weight Effects 0.000 claims 6
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims 5
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- -1 —O—C 1-4 haloalkyl Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63294504P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043782 WO2006060731A2 (en) | 2004-12-03 | 2005-12-02 | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521934A JP2008521934A (ja) | 2008-06-26 |
| JP2008521934A5 true JP2008521934A5 (https=) | 2009-01-22 |
Family
ID=36565812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544571A Withdrawn JP2008521934A (ja) | 2004-12-03 | 2005-12-02 | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070259894A1 (https=) |
| EP (1) | EP1824957A4 (https=) |
| JP (1) | JP2008521934A (https=) |
| KR (1) | KR20070085702A (https=) |
| CN (1) | CN101068916A (https=) |
| AU (1) | AU2005311672B2 (https=) |
| BR (1) | BRPI0518741A2 (https=) |
| CA (1) | CA2588466A1 (https=) |
| IL (1) | IL183383A0 (https=) |
| MX (1) | MX2007006637A (https=) |
| NO (1) | NO20073403L (https=) |
| NZ (1) | NZ555215A (https=) |
| RU (1) | RU2403066C2 (https=) |
| WO (1) | WO2006060731A2 (https=) |
| ZA (1) | ZA200703989B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7491819B1 (en) | 2004-05-28 | 2009-02-17 | Bristol-Myers Squibb Company | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| EP1819323B2 (en) | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| EP1904067B2 (en) | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| UA87884C2 (uk) | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP2116532B1 (en) | 2007-06-12 | 2011-12-07 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives as HIV protease inhibitors |
| US20100273203A1 (en) * | 2009-04-23 | 2010-10-28 | Board Of Trustees Of The University Of Arkansas | Methods and compositions for detecting metabolites |
| US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
| WO2011026112A1 (en) * | 2009-08-31 | 2011-03-03 | The Board Of Trustees Of The University Of Arkansas | Compositions comprising specific ugt inhibitors and methods of use thereof |
| US9649311B2 (en) | 2009-10-26 | 2017-05-16 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| US9095598B2 (en) | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| PL360944A1 (en) * | 2000-10-12 | 2004-09-20 | Merck & Co, Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| IL161337A0 (en) * | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| US20030215462A1 (en) * | 2001-12-21 | 2003-11-20 | Wacher Vincent J. | Use of UGT inhibitors to increase bioavailability |
| NZ540729A (en) * | 2002-12-27 | 2008-03-28 | Angeletti P Ist Richerche Bio | Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors |
| US20040192624A1 (en) * | 2003-03-24 | 2004-09-30 | Kempf Dale J. | Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP1904067B2 (en) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| EP1819323B2 (en) * | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
-
2005
- 2005-12-02 BR BRPI0518741-9A patent/BRPI0518741A2/pt not_active IP Right Cessation
- 2005-12-02 KR KR1020077012547A patent/KR20070085702A/ko not_active Withdrawn
- 2005-12-02 JP JP2007544571A patent/JP2008521934A/ja not_active Withdrawn
- 2005-12-02 CN CNA2005800413696A patent/CN101068916A/zh active Pending
- 2005-12-02 AU AU2005311672A patent/AU2005311672B2/en not_active Ceased
- 2005-12-02 US US11/792,189 patent/US20070259894A1/en not_active Abandoned
- 2005-12-02 WO PCT/US2005/043782 patent/WO2006060731A2/en not_active Ceased
- 2005-12-02 NZ NZ555215A patent/NZ555215A/en not_active IP Right Cessation
- 2005-12-02 EP EP05852867A patent/EP1824957A4/en not_active Withdrawn
- 2005-12-02 CA CA002588466A patent/CA2588466A1/en not_active Abandoned
- 2005-12-02 RU RU2007125130/15A patent/RU2403066C2/ru not_active IP Right Cessation
- 2005-12-02 MX MX2007006637A patent/MX2007006637A/es unknown
-
2007
- 2007-05-17 ZA ZA200703989A patent/ZA200703989B/xx unknown
- 2007-05-24 IL IL183383A patent/IL183383A0/en unknown
- 2007-07-02 NO NO20073403A patent/NO20073403L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514732A5 (https=) | ||
| JP2008521934A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2003509349A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| JP2004509061A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| JP2009535307A5 (https=) | ||
| JP2019526596A5 (https=) | ||
| JP2011505347A5 (https=) | ||
| JPWO2023027198A5 (https=) | ||
| JP2019515884A5 (https=) | ||
| CN100391455C (zh) | 靛红和羟吲哚衍生物的制药用途 | |
| JP2003503449A5 (https=) | ||
| JP2020500866A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| JP2004517843A5 (https=) | ||
| JP2010521417A5 (https=) | ||
| JP2024507788A5 (https=) | ||
| JP2008534453A5 (https=) | ||
| JP2006518731A5 (https=) | ||
| JP2002542298A5 (https=) | ||
| JP2011513377A5 (https=) | ||
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 |